Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

ClinicalTrials.gov ID: NCT02470910

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02470910. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning: A Pilot Study to Quantitate the Potential to Limit Radiation Dose to Normal Tissues.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This research study is evaluating whether a standard prostate MRI examination can improve radiation therapy planning for prostate cancer.

Study identification

NCT ID: NCT02470910
Recruitment status: Completed
Study type: Interventional
Phase: Not applicable
Lead sponsor: Dana-Farber Cancer Institute; Other
Enrollment: 15 participants

Conditions and interventions

Conditions

Interventions

Magnetic Resonance Imaging Device

Device

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 2015 (Type not available)
Primary completion: Jul 2018 (Actual)
Completion: Jul 2018 (Actual)
Last update posted: Dec 11, 2019

2015 – 2018

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Dana-Farber Cancer Institute	Boston	Massachusetts	02115	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02470910, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 11, 2019 · Synced Nov 13, 2026